AEGLE Therapeutics is a pioneering clinical-stage developer of novel, cell-free therapies utilizing extracellular vesicles (EVs) to deliver a natural biomolecular payload for the treatment of debilitating rare diseases, including dystrophic epidermolysis bullosa (DEB) and severe dermatological disorders.
With their proprietary EV harvesting technology, AEGLE Therapeutics harnesses the regenerative, immunomodulatory, and anti-inflammatory potential of MSC-derived EVs, such as exosomes, to develop AGLE-102, a therapeutic composite that has shown promising results in improving wound healing and stimulating cell function.
Generated from the website